Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.31 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928183 | 0.76 | CRBN (0.42) | MAPTTDP1L3MBTL1CRBNPDE7A | |
| SCHEMBL18281156 | 0.68 | ALDH1A1 (0.39) | MAPTKDM6BKDM4AKDM4DKDM3B | |
| SCHEMBL2054713 | 0.67 | CRBN (0.51) | MAPTTDP1L3MBTL1CRBN | |
| SCHEMBL9320806 | 0.67 | METAP2 (0.35) | KDM1ACRBNKDM6BKDM4AKDM4D | |
| SCHEMBL9931055 | 0.65 | ACACB (0.38) | KDM1A | |
| SCHEMBL9967142 | 0.64 | NPC1 (0.41) | — | |
| SCHEMBL5545337 | 0.63 | CRBN (0.41) | KDM1ACRBN | |
| SCHEMBL10973574 | 0.63 | HSD17B10 (0.66) | MAPTTDP1L3MBTL1 | |
| SCHEMBL20266094 | 0.62 | FFAR4 (0.34) | CTSB | |
| SCHEMBL24027009 | 0.62 | CA2 (0.33) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922337-B | ROR gamma modulators | 领先制药控股公司 | 2021-07-02 | — | — | CN | disclosed |
| EP-3319942-B1 | ROR-GAMMA MODULATORS | LEAD PHARMA B V (NL) | 2020-03-11 | — | — | EP | disclosed |
| US-20190040012-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2019-02-07 | — | — | US | disclosed |
| US-10118895-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2018-11-06 | — | — | US | disclosed |
| US-20180141909-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2018-05-24 | — | — | US | disclosed |
| EP-3319942-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-05-16 | — | — | EP | disclosed |
| WO-2016193468-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040012-A1 | ROR GAMMA (RORY) MODULATORS | RORC, RORA, RORB | MAPT 4711/4885TDP1 4736/4885L3MBTL1 1476/4885 |
| US-20180141909-A1 | ROR GAMMA (RORY) MODULATORS | RORC, RORA, RORB | MAPT 4775/4885TDP1 4670/4885L3MBTL1 1219/4885 |
| US-10118895-B2 | ROR gamma (RORγ) modulators | RORC, RORA, RORB | MAPT 4771/4885TDP1 4658/4885L3MBTL1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.